CRIS Current Research Information System

MONGIORGI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.674
AS - Asia 4.284
EU - Europa 3.950
AF - Africa 478
SA - Sud America 198
Continente sconosciuto - Info sul continente non disponibili 17
OC - Oceania 12
Totale 13.613
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.599
SG - Singapore 1.323
IT - Italia 1.148
VN - Vietnam 1.122
CN - Cina 941
GB - Regno Unito 665
DE - Germania 522
SE - Svezia 510
HK - Hong Kong 258
FR - Francia 200
RU - Federazione Russa 181
IN - India 180
BR - Brasile 143
NL - Olanda 137
TG - Togo 118
JP - Giappone 112
SC - Seychelles 112
IE - Irlanda 110
ZA - Sudafrica 85
CI - Costa d'Avorio 84
FI - Finlandia 84
KR - Corea 74
AT - Austria 57
UA - Ucraina 54
CA - Canada 53
NG - Nigeria 50
BG - Bulgaria 49
EE - Estonia 46
CH - Svizzera 43
HR - Croazia 41
JO - Giordania 39
BE - Belgio 31
BD - Bangladesh 26
ID - Indonesia 26
PK - Pakistan 24
PH - Filippine 21
PL - Polonia 21
TH - Thailandia 21
AR - Argentina 20
TR - Turchia 19
EU - Europa 15
UZ - Uzbekistan 14
TW - Taiwan 13
ES - Italia 12
IQ - Iraq 12
IR - Iran 11
MX - Messico 10
MY - Malesia 9
EC - Ecuador 8
GR - Grecia 8
IL - Israele 8
KE - Kenya 8
AU - Australia 7
EG - Egitto 7
LT - Lituania 7
UY - Uruguay 7
CO - Colombia 6
LB - Libano 6
RO - Romania 5
SA - Arabia Saudita 5
MA - Marocco 4
PE - Perù 4
PY - Paraguay 4
TN - Tunisia 4
MD - Moldavia 3
NZ - Nuova Zelanda 3
OM - Oman 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CL - Cile 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KZ - Kazakistan 2
LV - Lettonia 2
NP - Nepal 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
SS - ???statistics.table.value.countryCode.SS??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BZ - Belize 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LU - Lussemburgo 1
MK - Macedonia 1
Totale 13.601
Salva come PNG Salva come JPEG
Città #
Singapore 949
Southend 560
Ashburn 543
Chandler 456
Bologna 411
Fairfield 367
Santa Clara 280
Hong Kong 246
Ann Arbor 223
Hanoi 214
Ho Chi Minh City 212
San Jose 177
Houston 176
Wilmington 168
Woodbridge 156
Princeton 143
Seattle 141
Beijing 128
Cambridge 125
Lomé 118
Dong Ket 111
Dublin 110
Boardman 109
Dallas 90
Hefei 89
Abidjan 84
Frankfurt am Main 75
Tokyo 72
Lauterbourg 64
Milan 64
Padova 63
Helsinki 60
Nanjing 56
Westminster 56
New York 55
Los Angeles 53
Abeokuta 50
Sofia 49
Berlin 45
Council Bluffs 41
Vienna 41
Jinan 39
Redwood City 39
Amman 38
Seoul 36
Haiphong 35
Buffalo 34
Da Nang 34
Johannesburg 34
Bern 33
Saint Petersburg 33
Turin 33
Medford 31
Bremen 30
Brussels 30
Guangzhou 29
Redondo Beach 29
Changsha 28
Shanghai 27
Moscow 26
Redmond 26
Florence 25
Munich 25
San Diego 25
London 24
Nanchang 24
Shenyang 24
Rome 23
Parma 20
Toronto 20
Montreal 19
Amsterdam 18
Falkenstein 18
Sejong 18
Hebei 17
Jakarta 17
São Paulo 17
Des Moines 16
Orem 16
Chicago 15
Nuremberg 15
Hangzhou 14
Udine 14
Lappeenranta 13
Norwalk 13
Paris 13
Dearborn 12
Falls Church 12
Jiaxing 12
Biên Hòa 11
Brooklyn 11
Düsseldorf 11
Kyiv 11
Modena 11
Tappahannock 11
The Dalles 11
Tianjin 11
Turku 11
Warsaw 11
Yubileyny 11
Totale 8.494
Salva come PNG Salva come JPEG
Nome #
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 341
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 281
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 279
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 274
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 272
Nuclear phosphoinositides: Their regulation and roles in nuclear functions 271
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 256
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 252
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 249
Inositide-Dependent Nuclear Signalling in Health and Disease 245
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 226
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 224
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 222
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 221
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 219
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 219
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 217
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 215
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 213
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 207
Nuclear inositide signaling and cell cycle 207
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 207
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 206
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 205
Nuclear Inositide Signaling via Phospholipase C 201
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 200
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 200
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 197
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 196
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 195
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 194
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 186
The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world 185
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 183
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 182
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 181
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 180
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 173
Nuclear phospholipase C beta1 and cellular differentiation. 172
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 172
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 171
Protein kinase C involvement in cell cycle modulation 169
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 169
Lamin B1 as a key modulator of the developing and aging brain 168
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 165
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells 163
Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula 163
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 160
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 159
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 159
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 157
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 155
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 154
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 152
Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells 151
Nuclear inositide signaling in myelodysplastic syndromes. 151
Understanding the Ultra-Rare Disease Autosomal Dominant Leukodystrophy: an Updated Review on Morpho-Functional Alterations Found in Experimental Models 149
Recent advances in MDS mutation landscape: Splicing and signalling 146
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 144
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 142
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 139
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 137
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 137
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 137
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 125
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 123
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 121
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 120
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 118
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 112
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 111
null 103
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 103
null 95
null 81
null 72
null 71
Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation 63
Current therapy and new drugs: A road to personalized treatment of myelodysplastic syndromes 61
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 45
Totale 13.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021483 0 0 0 0 0 0 0 0 0 47 43 393
2021/20221.707 134 33 81 140 136 77 51 95 74 279 325 282
2022/20232.031 180 265 110 310 169 159 120 151 291 29 130 117
2023/2024840 51 101 82 83 98 121 28 41 74 73 49 39
2024/20252.067 121 272 188 134 350 130 187 90 39 137 97 322
2025/20264.162 363 486 406 276 530 278 551 143 853 276 0 0
Totale 13.946